SYRE Spyre Therapeutics, Inc. Common Stock

Sentiment & Price 3 ideas • 1 voices • 1 sources ▼
Sentiment Gauge
0
Bull
3
Bear
0
Watch
Bull 0% Bear 100%
Price & Sentiment
Loading chart...
Recent News Top Views ▼
No recent news for SYRE
No theses available
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
News✓
Loading...
All directions✓
▲ Long✓
▼ Short✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
15:02
Apr 13
A May MD Biotech investor
Short SYRE as the recent >$1B market cap addition is fundamentally unjustified, driven only by small, open-label data for a non-novel mechanism of action.
SYRE
HIGH
13:35
Apr 13
A May MD Biotech investor
Short SYRE to fade the massive 40% opening gap up, anticipating mean reversion or exhaustion of the initial buying pressure.
SYRE
MED
12:21
Apr 13
A May MD Biotech investor
Fade SYRE's Phase 2a data release, as the study's open-label design without a placebo group makes the results unreliable compared to established blinded studies.
SYRE
MED

About SYRE Analyst Coverage

Buzzberg tracks SYRE (Spyre Therapeutics, Inc. Common Stock) across 1 sources. 0 bullish vs 3 bearish calls from 1 analysts. Sentiment: mixed to bearish. 3 total trade ideas tracked.